Claims for Patent: 9,994,858

Summary for Patent: 9,994,858

Title:	Constructs for gene expression analysis
Abstract:	The present invention relates generally to constructs and their use in gene expression or gene regulation assays. More particularly, the present invention provides expression vectors and/or reporter vectors providing kinetics of protein expression with improved temporal correlation to promoter activity. Even more particularly, the invention provides expression vectors comprising a transcribable polynucleotide which comprises a sequence of nucleotides encoding a RNA element that modulates the stability of a transcript corresponding to the transcribable polynucleotide. The present invention provides, inter alia, novel vectors, useful for identifying and analysing cis- and trans-acting regulatory sequences/factors as well as vectors and genetically modified cell lines or organisms that are particularly useful for drug screening and drug discovery.
Inventor(s):	Daly; John (City Beach, AU)
Assignee:	Gene Stream PTY LTD (City Beach, Western Australia, AU)
Application Number:	11/542,982
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,994,858
Patent Claims:	1. A method for assaying an effect of a test agent on the activity of a non-constitutive promoter in cells of a first type, the method comprising: expressing in cells of the first type, in the presence and the absence of the test agent, a first polynucleotide comprising the coding sequence of a first polypeptide wherein the first polynucleotide is in a construct comprising, in operable linkage: a sequence comprising the non-constitutive promoter, the first polynucleotide and a nucleic acid sequence encoding a U-rich and/or AU-rich element that reduces the stability of a transcript produced from the expression of the first polynucleotide in both the presence and the absence of the test agent with the proviso that the construct lacks an element that stabilizes the transcript; measuring the level or the activity of the first polypeptide produced from the construct in the presence and the absence of the test agent; and comparing the measured level or the measured activity of the first polypeptide in the presence of the test agent to the measured level or the measured activity of the first polypeptide in the absence of the test agent wherein a difference indicates the effect of the test agent on the non-constitutive promoter; wherein the non-constitutive promoter, the coding sequence and the nucleic acid sequence are heterologous to each other. 2. The method according to claim 1, wherein the nucleic acid sequence is from a gene selected from the group consisting of c -fos, c fun, c-myc, GM-CSF, IL-3, TNF-alpha, IL-2, IL-6, IL-8, IL-10, Urokinase, bcl-2, SGLT1 (Na(+)-coupled glucose transporter), Cox-2 (cyclooxygenase 2), IL-8, PAI-2 (plasminogen activator inhibitor type 2), beta-adrenergic receptor or GAP43. 3. The method according to claim 1, wherein the element that reduced the stability of a transcript comprises an AU-rich element. 4. The method according to claim 1, wherein the nucleic acid sequence is selected from any one of SEQ ID NOS: 1-23. 5. The method according to claim 1, wherein the first polypeptide further comprises a protein destabilizing element. 6. The method according to claim 5, wherein the protein destabilizing element is a PEST sequence, an N-terminal destabilizing amino acid, or a ubiquitin. 7. The method according to claim 1, wherein the first polypeptide is a reporter protein. 8. The method according to claim 7, wherein the reporter protein is an enzymatic protein. 9. The method according to claim 7, wherein the reporter protein is a protein associated with the emission of light. 10. The method according to claim 7, wherein the reporter protein is a fluorescent protein or a luminescent protein. 11. The method according to claim 7, wherein the reporter protein is selected from the group consisting of: a luciferase, a green fluorescent protein, a red fluorescent protein, a SEAP and a CAT. 12. The method according to claim 7, wherein the reporter protein comprises firefly luciferase. 13. The method according to claim 7, wherein the reporter protein comprises Renilla luciferase. 14. The method according to claim 1, wherein the first polypeptide is a protein having at least a light-emitting activity and a selection marker activity. 15. The method according to claim 1, wherein the coding sequence of the first polypeptide is a chimeric gene comprising a coding sequence from a gene encoding a light-emitting protein selected from the group consisting of: a green fluorescent protein and a luciferase; and a coding sequence from a gene encoding a selectable marker protein selected from the group consisting of: kanamycin kinase, neomycin phosphotransferase, aminoglycoside phosphotransferase, puromycin N-acetyl transferase and puromycin resistance protein. 16. The method according to claim 1, wherein the non-constitutive promoter is dependent on a signal transduction pathway for modulation in the cells of the first type, and the test agent affects the signal transduction pathway.

Details for Patent 9,994,858

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2021-03-09